Maintenance Venetoclax Based Therapy Post Complete Remission in AML Fit Patients
Status: Recruiting
Location: See all (2) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
this study will explore the efficacy of maintenance SC cytarabine + venetoclax therapy as regard disease free survival (DFS) in AML fit patients who achieved CR after highly aggressive chemotherapy as bridge for BMT or if BMT will be delayed or canceled due to any other reason.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 60
Healthy Volunteers: f
View:
• Age : 18 - 60 years . Patients who are not eligible for immediate bone marrow transplantation. Newly diagnosed AML patients who attained CR after 1st line. Refractory / recurrant AML patients who attained CR after 2nd line .
Locations
Other Locations
Egypt
Sohag university
RECRUITING
Sohag
Sohag university hospital
RECRUITING
Sohag
Contact Information
Primary
Eman I Abdelshakour, Asst lect
Eman011065@med.sohag.edu.eg
+201063901450
Backup
Walaa G Mohamed, Lecturer
Time Frame
Start Date: 2025-09-01
Estimated Completion Date: 2027-09-01
Participants
Target number of participants: 80
Treatments
Active_comparator: Arm A
will receive SC cytarabine + venetoclax till bone marrow transplantation or for 12 cycles for patient will not undergo BMT , SC Cytarabine (20 mg) administrated on days 1-7 , Venetoclax (100 mg ) administrated on days 1-7 , Voriconazole 200 mg 1x2 administrated on days 1-7 + best supportive care BSC
No_intervention: Arm B
Patients Will receive Best supportive care( BSC )only
Related Therapeutic Areas
Sponsors
Leads: Sohag University